Comparative Pharmacology
Head-to-head clinical analysis: BENZAMYCIN versus NEOSPORIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENZAMYCIN versus NEOSPORIN.
BENZAMYCIN vs NEOSPORIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BENZAMYCIN (benzoyl peroxide and clindamycin) combines the keratolytic and antimicrobial actions of benzoyl peroxide with the antibacterial effect of clindamycin, a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.
Neosporin is a combination of three antibiotics: neomycin (aminoglycoside) inhibits bacterial protein synthesis by binding to 30S ribosomal subunit; polymyxin B (polymyxin) disrupts bacterial cell membrane integrity; bacitracin (polypeptide) inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier.
Topical: Apply a thin layer to affected areas twice daily (morning and evening). Each gram contains 30 mg benzoyl peroxide and 30 mg erythromycin.
Apply a thin layer topically to the affected area 1-3 times daily. May be covered with a sterile bandage.
None Documented
None Documented
2.5-3.5 hours in adults with normal renal function; may be prolonged to 4-6 hours in patients with hepatic impairment
Variable based on severity of renal impairment. Normal renal function: 2-3 hours for neomycin (main component); polymyxin B: 4-6 hours. In anuria: half-life extends to 72-96 hours for neomycin.
Renal excretion: ~70% (30% as unchanged drug, 40% as active metabolite N-desmethylclindamycin); biliary/fecal: ~30%
Renal excretion accounts for >90% of elimination; primarily glomerular filtration with minimal tubular secretion. Small biliary/fecal elimination (<5%).
Category C
Category C
Topical Antibiotic
Topical Antibiotic